Lane W J, Dias S, Hattori K, Heissig B, Choy M, Rabbany S Y, Wood J, Moore M A, Rafii S
Division of Hematology-Oncology, Weill Medical College of Cornell University, Ithaca, NY 10021, USA.
Blood. 2000 Dec 15;96(13):4152-9.
Despite the discovery of thrombopoietin (TPO) and its contribution to megakaryocytopoiesis, the exact mechanisms and sites of platelet production are unknown. It has been shown that mature megakaryocytes (MKs) functionally express the stromal-derived factor 1 (SDF-1) receptor, CXCR4. SDF-1-induced migration of mature MKs through endothelial cell layers results in increased platelet production. Because the migration of polyploid MKs from the bone marrow microenvironment requires remodeling of the perivascular extracellular matrix, it was hypothesized that mature polyploid MKs may express matrix metalloproteinases (MMPs), facilitating their exit into the bone marrow extravascular space. In this report, it is demonstrated that SDF-1 induces the expression and release of gelatinase B (MMP-9) by purified mature polyploid human MKs and an adeno-CXCR4-infected megakaryocytic cell line. Neutralizing antibody to MMP-9, but not MMP-2, blocked SDF-1-induced migration of MKs through reconstituted basement membrane, suggesting that expression of MMP-9 is critical for MK migration. Incubation of mature MKs with a synthetic MMP inhibitor, 5-phenyl-1,10-phenanthrolene, resulted in the inhibition of platelet formation, suggesting that the expression of MMPs is not only critical for megakaryocyte migration but also for subsequent platelet release. Confirming these results, adeno-SDF-1 injection into normal mice resulted in increased platelet counts, a process that could be blocked by a synthetic MMP inhibitor. These results suggest mobilization of MKs involves sequential expression and activation of chemokine receptors such as CXCR4, MMP-9, followed by transendothelial migration. MMP inhibitors may have potential use in the treatment of thrombotic and myeloproliferative disorders. (Blood. 2000;96:4152-4159)
尽管血小板生成素(TPO)已被发现且对巨核细胞生成有作用,但血小板产生的确切机制和部位仍不清楚。研究表明,成熟巨核细胞(MKs)功能性表达基质衍生因子1(SDF-1)受体CXCR4。SDF-1诱导成熟MKs穿过内皮细胞层迁移,从而增加血小板生成。由于多倍体MKs从骨髓微环境迁移需要血管周围细胞外基质重塑,因此推测成熟多倍体MKs可能表达基质金属蛋白酶(MMPs),促进其进入骨髓血管外间隙。在本报告中,证明SDF-1可诱导纯化的成熟多倍体人MKs和腺病毒-CXCR4感染的巨核细胞系表达并释放明胶酶B(MMP-9)。抗MMP-9而非MMP-2的中和抗体可阻断SDF-1诱导的MKs穿过重组基底膜的迁移,表明MMP-9的表达对MK迁移至关重要。用合成MMP抑制剂5-苯基-1,10-菲咯啉孵育成熟MKs,可抑制血小板形成,提示MMPs的表达不仅对巨核细胞迁移至关重要,对随后的血小板释放也很关键。证实这些结果的是,向正常小鼠注射腺病毒-SDF-1可导致血小板计数增加,这一过程可被合成MMP抑制剂阻断。这些结果表明,MKs的动员涉及趋化因子受体如CXCR4、MMP-9的顺序表达和激活,随后是跨内皮迁移。MMP抑制剂可能在血栓形成性疾病和骨髓增殖性疾病的治疗中具有潜在用途。(《血液》。2000年;96:4152 - 4159)